Syn2bio S.A., a biotechnology company, engages in the research and commercialization of Cardiac Marker, a radiopharmaceutical for diagnostic testing of heart disease in the field of myocardial perfusion. The company's flagship project is the cardiotracer project, a radiopharmaceutical designed for testing myocardial perfusion and diagnosis of coronary artery disease. Additionally, it operates The Centre for Research on New Compounds, a unit engaged in the search for new pharmaceutical compounds and their further study, registration, and market launch as a medicinal product. Syn2bio S.A. was incorporated in 2025 and is based in Warsaw, Poland.
Frequently asked questions
What sector does SYN2BIO SPÓŁKA AKCYJNA (S2B) operate in?
SYN2BIO SPÓŁKA AKCYJNA belongs to the Other sector and operates in the Biotechnology industry.
What is SYN2BIO SPÓŁKA AKCYJNA (S2B) current stock price?
As of the latest data, SYN2BIO SPÓŁKA AKCYJNA stock price is PLN 66.80, with a previous close of PLN 66.50. SYN2BIO SPÓŁKA AKCYJNA gained PLN 0.30 in the last trading session, representing a 0.45% increase.
What is SYN2BIO SPÓŁKA AKCYJNA (S2B) current market capitalization?
SYN2BIO SPÓŁKA AKCYJNA market cap is approximately 583.11 million.
What is SYN2BIO SPÓŁKA AKCYJNA (S2B) Earnings Per Share (EPS)?
The trailing EPS is -PLN 2.71.
Does SYN2BIO SPÓŁKA AKCYJNA (S2B) pay dividends?
No. SYN2BIO SPÓŁKA AKCYJNA does not pay a dividend.
What is SYN2BIO SPÓŁKA AKCYJNA (S2B) beta (volatility) score?
SYN2BIO SPÓŁKA AKCYJNA has a beta of -0.010, indicating lower volatility than the overall market.
